Prolongation of the QT interval by ketanserin.

Abstract

In hypertensive patients single doses of ketanserin 40 mg prolonged the corrected QT interval (QTc) for at least 8 hours, with a maximal increase of 35 ms (P less than 0.001, n = 6) after 2 hours. During chronic dosing (20 and 40 mg b.d.) the QTc was further prolonged, by 46 and 45 ms respectively. QTc prolongation after treatment with a mean dose of 73 mg/day for 7 weeks (n = 26) was significantly related to body weight (r = -0.58, P less than 0.01), and to the dose of ketanserin corrected for body weight (r = 0.63, P less than 0.01), but not to plasma concentrations of ketanserin, ketanserinol, potassium or calcium. High doses of ketanserin (mean dose 167 mg/day, n = 9) increased the QTc by 40 ms (P less than 0.001), with prolongation of up to 80 ms in individual patients. Treatment with ketanserin at doses proposed for clinical use (40-80 mg/day) may carry a risk of ventricular arrhythmias.

• Authors: H A Cameron, P C Waller, L E Ramsay
• Journal: Postgraduate medical journal (Postgrad Med J) Vol. 64 Issue 748 Pg. 112-7 (Feb 1988) ISSN: 0032-5473 [Print] England
• PMID: 3050936 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ketanserin

Topics

• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Electrocardiography
• Female
• Heart (drug effects, physiopathology)
• Humans
• Hypertension (drug therapy, physiopathology)
• Ketanserin (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Random Allocation